Biogen Inc’s Revenue by Segment (2016-2022)
You need Pro Plan to access KPI data.
Get 60% off on Pro
- KPI data & segment financials on US stocks
- Financial data on thousands of stocks
- Download data in xlsx and csv formats
Discount ends in:
00
Days
00
Hours
00
Mins.
00
Seconds
About
This statistic highlights Biogen Inc’s Revenue by Segmen, split between Product, anti-CD20 therapeutic programs and other segments, reported on a quarterly basis from Q1 2016 onwards.
More information
Contact the Analyst
Become a smarter investor today.
Access Business Quant for as low as $19/month
Become a smarter investor today.
Access KPIs & Segment Financials on US stocks
This statistic highlights Biogen Inc’s Revenue by Segmen, split between Product, anti-CD20 therapeutic programs and other segments, reported on a quarterly basis from Q1 2016 onwards.
Product, net: Biogen’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer’s disease; and FUMADERM for the treatment of acute plaque psoriasis.
Revenue from anti-CD20 therapeutic programs: is referred to as RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
Other Revenue: Revenue earned from collaborations and other relationships, technical development agreements, manufacturing services agreements, and royalty revenue on biosimilar products with Samsung Bioepis.
Biogen Inc’s Revenue by Segment
| Revenue by Segment | Q3 2020 | Q2 2021 | Q3 2021 | Revenue contribution in Q3 2021 |
| Product, Net | $2.69 | $2.24 | $2.21 | 79% |
| Revenue from Anti-CD20 therapeutic programs | $0.56 | $0.44 | $0.16 | 15% |
| Other Revenue | $0.13 | $0.10 | $0.16 | 6% |
| Total | $3.38 | $2.78 | $2.78 | 100% |
Product, net: The revenue generated from the product net was $2.206 billion in Q3 2021. It showed a decline of around 18% on a year-on-year basis from $2.690 billion in Q3 2020. This segment contributed 79% of the total revenue of Q3 2021.(All the figures are in billions, except percentages)
Revenue from Anti-CD20 therapeutic programs: This program has earned $0.415 billion in Q3 2021 which on a year-on-year basis showed a decline of 26% from $0.560 billion in Q3 2020. It contributes to 15% of the total revenue of Q3 2021.
Other revenues: Revenue from other sources such as royalties and collaborations have earned a total of $0.158 billion (or $ 518 million approximate) in Q3 2021, which is a 26% growth from $0.126 billion (or $126 million, approximate) in Q3 2020. This also constitutes 6% of the total revenue generated in Q3 2021.
About the Company
Biogen Inc. was founded by several prominent biologists in Geneva-Walter Gilbert, Kenneth Murray, and Heinz Schaller. It is a Biotechnology pharmaceutical company, with its core growth areas being Immunology, Neuropathic pain, and Acute Neurology. It is solving problems with its products like TECFIDERA, and TYSABRI, treating several neuropathic diseases like relapsing MS and primary progressive MS and ADUHELM for treating Alzheimer’s disease and other potential anti-CD20 therapies with self-research and development and other collaboration agreements.
Did you like Biogen Inc’s Revenue by Segment statistic?
Access more such KPI (key performance indicator) data points, on thousands of US stocks, with Business Quant.
You can get started here.
More data on US Stocks
All articles loaded
No more articles to load
Our Plans
Always know what you’ll pay. No hidden costs or surprises.
- Annual
- Monthly
60% discount until this Sunday
Pro
For serious investing
-
Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
-
Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
-
Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$49
$19
per month*
Enterprise
For tailored workflows
-
All of Pro plan Get unfettered access to all our dashboards and dossiers.
-
Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
* Billed annually, local taxes extra.
60% discount on Annual plan
Pro
For serious investing
-
Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
-
Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
-
Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$49
per month*
Enterprise
For tailored workflows
-
All of Pro plan Get unfettered access to all our features.
-
Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
* Local taxes extra.
